Details of the Drug Combinations

General Information of This Drug (ID: DMBD4K3)

Drug Name
Selinexor   DMBD4K3
Synonyms Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Approved [1]
Liposarcoma 2B59 Phase 3 [2]
Neuroendocrine cancer 2B72.1 Phase 3 [2]
Acute myeloid leukaemia 2A60 Phase 2 [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
Diffuse large B-cell lymphoma 2A81 Phase 2 [3]
Recurrent glioblastoma 2A00.00 Phase 2 [2]
Solid tumour/cancer 2A00-2F9Z Phase 2 [5]
⏷ Show the Full List of Indication(s)
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Selinexor + Panobinostat DC7F2XA Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [6]
Selinexor + Idarubicin DC1FKPA Idarubicin Glioblastoma? (Cell Line: T98G) [6]
------------------------------------------------------------------------------------
39 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Ruxolitinib + Selinexor DC5W7CV Ruxolitinib Multiple Myeloma in Relapse [7]
Selinexor + Acetaminophen DCS0K91 Acetaminophen Solid Tumor [8]
Selinexor + Cladribine DC7CTPG Cladribine Acute Myeloid Leukemia [9]
Selinexor + Dexamethasone DCHOGFF Dexamethasone Multiple Myeloma [10]
Selinexor + Ifosfamide DCNHDKM Ifosfamide Non-rhabdomyosarcoma [11]
Selinexor + Dexamethasone DC4GGQ5 Dexamethasone Multiple Myeloma [10]
Selinexor + Dexamethasone DC7VXON Dexamethasone Multiple Myeloma [12]
Selinexor + Lomustine DC8H0S7 Lomustine Glioblastoma Multiforme [13]
Selinexor + Lenalidomide DCWBO0J Lenalidomide Refractory Multiple Myeloma [14]
Selinexor + Dexamethasone DCZP0J4 Dexamethasone Multiple Myeloma [10]
Selinexor + Irinotecan DC320AO Irinotecan Esophageal Cancer [15]
Selinexor + Temozolomide DCBIP9F Temozolomide Gliosarcoma [16]
Selinexor + Docetaxel DCBLXMC Docetaxel Non-small Cell Lung Cancer [17]
Selinexor + Venetoclax DCDJGS3 Venetoclax Diffuse Large B-cell Lymphoma [18]
Selinexor + Dexamethasone DCE97EV Dexamethasone Amyloid [19]
Selinexor + RG7388 DCHAIVG RG7388 Rhabdoid Tumor [20]
Selinexor + Docetaxel DCLMORP Docetaxel Non-Small Cell Lung Carcinoma (NSCLC) [21]
Selinexor + Imatinib DCON821 Imatinib Maximum Tolerated Dose [22]
Selinexor + Irinotecan DCU18NJ Irinotecan Solid Tumor Malignancy [23]
Talazoparib + Selinexor DC7Y05T Talazoparib Advanced Refractory Solid Tumors [24]
Selinexor + Dexamethasone DCE9MVM Dexamethasone Myeloma Multiple [25]
Selinexor + Dexamethasone DCIOWYI Dexamethasone Multiple Myeloma [26]
Selinexor + Dexamethasone DC5DBY0 Dexamethasone Multiple Myeloma, Refractory [27]
Selinexor + Dexamethasone DC7R8Y5 Dexamethasone Multiple Myeloma [28]
Selinexor + Dexamethasone DC8ZTR0 Dexamethasone Multiple Myeloma in Relapse [29]
Selinexor + Dexamethasone DCAKB2J Dexamethasone Multiple Myeloma, Refractory [27]
Selinexor + Venetoclax DCD4CLW Venetoclax AML [30]
Selinexor + Venetoclax DCV3MVY Venetoclax AML, Adult [31]
Selinexor + Dexamethasone DCVY538 Dexamethasone Relapsed and Refractory Multiple Myeloma [32]
Selinexor + Idarubicin DCW7GQD Idarubicin Acute Myeloid Leukemia (Relapsed/Refractory) [33]
Selinexor + Dexamethasone DCWX30C Dexamethasone Multiple Myeloma [34]
Selinexor + Dexamethasone DCZGR39 Dexamethasone Multiple Myeloma in Relapse [29]
Selinexor + Dexamethasone DC3P6BL Dexamethasone Multiple Myeloma [35]
Selinexor + Gemcitabine DC71208 Gemcitabine Sarcoma,Soft Tissue [36]
Selinexor + CATECHIN DCKRRV7 CATECHIN Acute Myeloid Leukemia (Relapsed/Refractory) [37]
Selinexor + Lenalidomide DCO75M8 Lenalidomide Multiple Myeloma [28]
Ruxolitinib + Selinexor DC49UIQ Ruxolitinib Myelofibrosis [38]
Selinexor + Dexamethasone DCERTZX Dexamethasone Multiple Myeloma [39]
Selinexor + Dexamethasone DCXMXNB Dexamethasone Multiple Myeloma [40]
------------------------------------------------------------------------------------
⏷ Show the Full List of 39 DrugCom(s)

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT04349098) Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection. U.S. National Institutes of Health.
5 ClinicalTrials.gov (NCT02025985) Phase II Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies. U.S. National Institutes of Health.
6 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
7 ClinicalTrials.gov (NCT06225310) A Trial of Selinexor, Ruxolitinib and Methylprednisolone
8 ClinicalTrials.gov (NCT01607905) Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
9 ClinicalTrials.gov (NCT02416908) Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
10 ClinicalTrials.gov (NCT02343042) Selinexor and Backbone Treatments of Multiple Myeloma Patients
11 ClinicalTrials.gov (NCT06239272) NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
12 ClinicalTrials.gov (NCT02389543) Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
13 ClinicalTrials.gov (NCT04421378) A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
14 ClinicalTrials.gov (NCT04519476) Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
15 ClinicalTrials.gov (NCT02283359) Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
16 ClinicalTrials.gov (NCT04216329) Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
17 ClinicalTrials.gov (NCT03095612) Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
18 ClinicalTrials.gov (NCT03955783) Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies
19 ClinicalTrials.gov (NCT04984330) Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
20 ClinicalTrials.gov (NCT05952687) Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors
21 ClinicalTrials.gov (NCT04256707) Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
22 ClinicalTrials.gov (NCT04138381) Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)
23 ClinicalTrials.gov (NCT05177276) Selinexor Combination Ph 1 Study
24 ClinicalTrials.gov (NCT05035745) Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
25 ClinicalTrials.gov (NCT04843579) Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
26 ClinicalTrials.gov (NCT05900882) SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease
27 ClinicalTrials.gov (NCT04414475) A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM
28 ClinicalTrials.gov (NCT05820763) Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
29 ClinicalTrials.gov (NCT04925193) Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
30 ClinicalTrials.gov (NCT05736978) Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
31 ClinicalTrials.gov (NCT05736965) A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Nave Participants With Acute Myeloid Leukemia
32 ClinicalTrials.gov (NCT05530421) Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
33 ClinicalTrials.gov (NCT02249091) A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
34 ClinicalTrials.gov (NCT02628704) Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
35 ClinicalTrials.gov (NCT02336815) Selinexor Treatment of Refractory Myeloma
36 ClinicalTrials.gov (NCT06114004) Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)
37 ClinicalTrials.gov (NCT05951855) Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients
38 ClinicalTrials.gov (NCT04562389) Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
39 ClinicalTrials.gov (NCT03110562) Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
40 ClinicalTrials.gov (NCT05028348) A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma